The GLP-1 market is set to hit over $30 billion by 2030. Intellectual property litigation and FDA crackdowns have led to a boom in M&A and partnership activity. Long-term patient effects have yet to be fully realized. The future of GLP-1s is bright, but ownership, …
On April 22 and 23, 2026, the Association of Medical Diagnostic Manufacturers will hold its Annual Meeting at the Canopy by Hilton in Bethesda, MD. The day and a half meeting, which is preceded by the group’s annual IVD 510(k) conference will be kicked off …
Hyman, Phelps & McNamara, P.C., one of the nation’s largest boutique food and drug regulatory law firms, seeks to add a junior to mid-level associate with two to five years of experience to its healthcare compliance team. This associate should have experience providing advice to life …
Hyman, Phelps & McNamara, P.C. (HP&M) seeks to add a 3rd to 6th year associate to our busy drug development team. Our team of lawyers and regulatory experts assists clients with a wide variety of FDA regulatory issues arising in the pre-market arena for clients developing …
As regulatory frameworks for orphan medicinal products continue to evolve on both sides of the Atlantic, understanding the practical and strategic implications is increasingly important. On M April 14th, 10:00 to 11:00 ET, Pinsent Masons and Hyman, Phelps & McNamara, P.C. are pleased to host …
Hyman, Phelps & McNamara, P.C., one of the nation’s largest boutique food and drug regulatory law firms, seeks to add a junior to mid-level associate with three to five years of experience to its healthcare compliance team. This associate should have experience providing advice to life …
As regulatory frameworks for orphan medicinal products continue to evolve on both sides of the Atlantic, understanding the practical and strategic implications is increasingly important. On March 17th from 10:00 to 11:00 ET, Pinsent Masons and Hyman, Phelps & McNamara, P.C. are pleased to host a …
Hyman, Phelps & McNamara, P.C. (HPM) is hosting a complimentary webinar, titled “From Prototype to Approval: US Regulatory Strategy for MedTech Startups.” The webinar is scheduled for March 25, 2026 (11:00am to 12:00pm ET). Bringing a medical device from prototype to market requires more than innovation—it …
The American Conference Institute’s (ACI’s) Annual Paragraph IV Disputes Conference is scheduled to take place from April 21-22, 2026 at The Times Center, New York, NY. Join the nation’s most respected forum for pharmaceutical patent litigation as it returns for its 22nd edition. This is …
Controlled substances are necessary for the medical care of patients, but recent diversion by pharmacists, physicians, nurses and other healthcare professionals illustrates the vulnerability of hospitals. Hospitals that fail to provide effective controls and procedures to guard against theft and diversion of controlled substances pose …
The American Conference Institute’s (“ACI”) milestone 10th Anniversary edition of its Advanced Summit on Food Law, Compliance and Regulation is scheduled to take place from April 28–29, 2026 at the Hilton Chicago/Magnificent Mile Suites in Chicago, IL. Since ACI’s last summit, the food industry continues to …
The American Conference Institute’s (“ACI”) FDA Boot Camp returns March 25-26, 2026, at the New York City Bar, New York, NY. This foundational training brings together life sciences attorneys, in-house counsel, and compliance professionals to dissect FDA law, policy, and enforcement trends. What You’ll Gain: A clear …
The American Conference Institute’s (“ACI”) 13th Annual Legal, Regulatory & Compliance Forum on Cosmetics & Personal Care Products returns March 12-13, 2026 at the New York City Bar, New York, NY. The forum once again brings together the legal and regulatory leaders of the cosmetics …
Hyman, Phelps & McNamara, P.C. Director Kalie E. Richardson will be moderating a Food and Drug Law Institute webinar this coming Wednesday on Ensuring Effective Responses to FDA 483s and Warning Letters. This webinar will cover fundamental considerations for responding to FDA 483s and Warning …
Artificial Intelligence (“AI”) in the life sciences has moved from pilot to production, across discovery, trials, and post-market. With the EU AI Act taking effect, evolving FDA expectations, and looming litigation and enforcement risk, getting it right has never mattered more. Join the American Conference Institute …
